melanoma inhibitori activ mia protein secret malign melanoma recent studi reveal interact mia epitop extracellular matrix protein includ fibronectin structur homolog mia bind site alpha4beta1 integrin result complex interact mia molecul bind alpha4beta1 integrin cell immun system express alpha4beta1 integrin vla-4 investig whether mia modul function human leukocyt here describ effect mia activ human pbmc auto-/allogen lymphokin-activ killer cell lak cytotox human mia-neg glioma cell line mia-posit melanoma cell line vitro mia inhibit pha- il-2-induc human pbmc prolifer dose-depend manner h-tdr incorpor cell count respect ad cell cultur prior mitogen stimul addit both autolog allogen htz-17 htz-243 htz-374 antitumor lak cytotox reduc addit exogen rhmia 500 ng/ml f.c consequ endogen inhibit mia express human melanoma cell mia-specif phosphorothio antisens oligonucleotid enhanc autolog lak-cell activ same level observ mia-neg human hmb melanoma cell express mia-antisens construct result indic mia contribut immunosuppress frequent malign melanoma inhibit cellular antitumor immun reaction antagon mia activ us antisens techniqu repres novel therapeut strategi treatment malign melanoma
recombin plasmid dna attenu poxvirus under develop cancer infecti diseas vaccin present result phase clinic trial recombin plasmid dna modifi vaccinia ankara mva both encod melanoma tumor antigen cytotox lymphocyt ctl epitop hla-a*0201-posit patient surgic treat melanoma receiv prime-boost dna/mva homolog mva-onli regimen vivo tetram analysi perform multipl time point provid detail kinet vaccin-driven ctl respons specif high-affin melan-a 26-35 analogu epitop melan-a26-35-specif ctl gener 2/6 patient receiv dna/mva detect first mva inject 4/7 patient receiv mva vivo elispot analysi vitro prolifer assai confirm effector function ctl respons smallpox-vaccin well vaccinia-naiv patient defin anti-vaccinia antibodi respons demonstr elisa assai observ ctl respons gener recombin epitop magnitud respons 0.029-0.19 cd8 cell level usual acut viral infect suggest ensur high number ctl specif multipl recombin epitop deeper understand interplai ctl respons specif viral vector recombin epitop requir
solubl tumour necrosi factor receptor type stnf-ri evalu sera patient epidermodysplasia verruciformi patient cutan wart actin keratos squamou cell carcinoma basal cell carcinoma specif enzym-link immunobiolog assai patient widespread epidermodysplasia verruciformi lesion level both stnf-rs normal rang both type stnf-rs significantli increas patient wart level stnf-ri significantli increas patient multipl actin keratos squamou cell carcinoma basal cell carcinoma increas level circul stnf-rs facilit develop cutan tumour normal level stnf-rs patient epidermodysplasia verruciformi least partial contribut slow growth low metastat potenti cancer patient
sever environment genet factor involv skin cancer induct howev exposur chemic carcinogen solar ultraviolet radiat primarili respons sever skin diseas includ skin cancer chronic exposur solar radiat skin lead basal cell squamou cell carcinoma melanoma chemoprevent skin cancer consumpt natur occur botan appear practic approach world-wide interest consider increas us botan sunscreen us protect ideal becaus inadequ us incomplet spectral protect toxic silymarin plant flavonoid isol seed milk thistl silybum marianum shown chemoprevent effect chemic carcinogenesi well photocarcinogenesi variou anim tumor model topic treatment silymarin inhibit 12-dimethylbenz anthracen-initi sever tumor promot like 12-o-tetradecanoylphorbol-13-acet mezerein benzoy peroxid okada acid induc skin carcinogenesi mous model similarli silymarin prevent uvb-induc skin carcinogenesi wide rang vivo mechanist studi indic silymarin possess antioxid anti-inflammatori immunomodulatori properti lead prevent skin cancer vivo anim model avail experiment inform suggest silymarin promis chemoprevent pharmacolog safe agent exploit test skin cancer human system moreov silymarin favor supplement sunscreen protect provid addit anti-photocarcinogen protect
malign melanoma soft part mmsp call clear cell sarcoma tendon aponeuros cytogenet character q13 q12 result chimer ewsr1/atf1 gene mmsp share number morpholog histolog immunohistochem featur malign melanoma skin caus diagnost difficulti distinct mmsp metastat malign melanoma unknown primari site recent high incid activ mutat kinas domain braf gene report malign melanoma skin most common mutat v599e t1796a substitut exon lead exchang valin glutam acid posit 599 becaus extens clinic histolog immunohistochem similar melanoma decid analyz whether mmsp mutat braf gene eight mmsp ewsr1/atf1 chimer transcript on soft tissu metastasi malign melanoma skin on malign melanoma cell line examin both convent melanoma exon t1796a v599e mutat none mmsp found harbor mutat exon braf gene data emphas mmsp convent malign melanoma develop through differ genet pathwai
antitumor cytotox cell cell express nk-associ receptor regul interact cell surfac killer immunoglobulin-like receptor kir cd94/nkg2 heterodim mhc class ligand target cell test hypothesi kir hla polymorph kir/hla combin contribut tumorigenesi associ studi perform patient malign melanoma differ stage diseas control data show frequenc inhibitori activ kir gene kir genotyp differ significantli healthi individu melanoma patient hla haplotyp distribut show statist signific increas frequenc a*01-b*35-cw*04 0.069 0.000 &lt 0.05 19.9 a*01-b*08-drb1*03 0.079 0.019 &lt 0.05 4.5 a*24-b*40-drb1*11 0.026 0.000 &lt 0.05 7.1 melanoma patient compar healthi control individu homozyg group hla-c ligand frequent patient group compar control cohort 31.5 &lt 0.017 addit observ increas frequenc 88.0 68.5 0.017 2.80 kir2dl2/2dl3 combin group hla-c ligand presenc kir absenc put ligand decreas 12.0 31.5 0.017 patient group furthermor increas frequenc activ kir2ds1 absenc put hla-c ly80 ligand found melanoma patient 16.0 9.2 contrast kir2ds2 absent patient 38.0 25.9 presumpt hla-c asn80 ligand present slightli higher incid kir3dl1 combin effect bw4 thr80 ligand patient primari 20.8 compar metastat 4.2 diseas data obtain studi impli direct associ kir gene content genom presenc malign melanoma melanoma progress howev hla haplotyp predispos bulgarian popul furthermor distinct kir/hla ligand combin relev develop malign wherebi inhibit overrid activ cell cell express nk-associ receptor turn facilit tumor escap progress
malign transform cell frequent associ abnorm human leukocyt antigen hla express mhc class loss down-regul cancer cell major immun escap rout us larg varieti human tumour evad antitumour immun respons mediat cytotox lymphocyt goal studi explor hla genotyp phenotyp varieti melanoma tumour cell line total melanoma cell line characteris hla class genotyp addit cell line analys hla class cell surfac molecul express flow cytometri unexpectedli found 19.7 melanoma cell line homozyg hla class genotyp sometim associ hla class homozygos 8.79 sometim 10.98 frequenc homozygos significantli higher compar control group 1.6 identifi reason underli high frequenc hla homozygos search genom delet us eight pair highli polymorph microsatellit marker cover entir extend hla complex short arm chromosom result compat hemizyg delet suggest loss heterozygos chromosom arm common featur melanoma cell line fact autolog normal dna patient avail test retent case heterozygos number microsatellit marker indic hemizyg delet rest case marker show singl allel pattern indic probabl loss part whole chromosom result led conclud loss heterozygos chromosom nonrandom possibl immunolog relev event human malign melanoma well-establish alter hla class phenotyp detect flow cytometri correspond hla class total loss hla-abc specif hla-b locu down-regul
previou cytogenet studi mycosi fungoid sezari syndrom identifi larg poorli defin area chromosom delet chromosom 10q report extens fine-map allelotyp studi us microsatellit marker region 10q22.3-10q26.13 allel loss identifi loss heterozygos analysi case sampl show similar pattern allel loss identif two discret region delet mutual exclus two case first region delet 10q23.33-10q24.1 around microsatellit marker d10s185 2.77 gene identifi includ three kif11 hhex hell function dysregul critic second region delet 10q24.33-10q25.1 around microsatellit marker d10s530 3.92 encod gene major poorli identifi function extens allelotyp studi provid basi futur highli select candid gene analys
all-tran-retino acid atra exert effect via apoptosi cell cycl re-distribut howev mechan behind effect fulli understood studi us model system match primari metastat melanoma cell investig whether express id1 p16 protein involv atra-induc apoptosi cell cycl re-distribut melanoma cell expos 0.1 microm atra 1-96 apoptosi cell cycl measur flow cytometri express id1 p16 protein examin western blot immunocytochemistri exposur atra found mark increas apoptosi cell cycl re-distribut both primari metastat melanoma cell express level id1 protein decreas p16 increas dose- time-depend p&lt 0.05 manner treatment atra alter protein pronounc primari melanoma cell match metastas p&lt 0.05 data suggest alter id1 p16 protein involv atra-induc apoptosi cell cycl re-distribut melanoma express profil id1 p16 protein provid molecular evid better chemotherapi primarili earli stage melanoma
e7070 synthet chloro-indolyl sulphonamid develop anti cancer agent phase studi patient metastat melanoma receiv 700 mg/m e7070 60-min infus repeat everi week therapi well toler on patient receiv cours treatment minor respons independ radiolog review e7070 doe warrant develop singl agent treatment metastat melanoma
background us genet modifi autolog tumor cell appear promis approach cancer therapi phase i/ii trial undertaken defin feasibl safeti antitumor effect autolog vaccin prepar transfer tag7/pgrp-s gene malign melanoma renal cell carcinoma cell patient method twenti-on patient dissemin malign melanoma four metastat renal cell carcinoma enrol studi cytoreduct perform case prior therapi autolog tumor cell transfect tag7/pgrp-s gene irradi inject intraderm everi week result vaccin well toler patient clinic signific sign toxic delai-type hypersensit observ case antitumor immun respons observ patient complet partial respons howev minor respons achiev on patient renal cell carcinoma stabil neoplast diseas observ eight patient seven malign melanoma on renal cell carcinoma median time tumor progress month conclus approach suggest here appear well toler produc number durabl clinic effect studi requir determin whether promis effect immun activ will result actual clinic benefit patient malign melanoma renal cell carcinoma
object few popul-base incid analys vulvar melanoma includ unit state sweden current avail studi incid vulvar melanoma larg popul-base cancer registri east germani compar find unit state sweden method extract vulvar melanoma regist 1976 1989 former nation cancer registri german democrat republ gdr three east german cancer registri feder state sachsen brandenburg mecklenburg-vorpommern period 1998 2002 calcul ag-specif ag-standard incid rate us world standard popul result on hundr two case 1976-1989 former gdr twenti-five case vulvar melanoma 1998-2002 three feder state regist ag-standard incid rate world standard popul remain constant period 1976 1989 rang 0.26 0.52 case per million 1998 2002 incid rate 0.48 per million ratio regist vulvar melanoma skin melanoma ratio vagin melanoma skin melanoma 314 ag diagnosi period 1976 1989 lower among women vulvar melanoma median ag year compar women vulvar tumor melanoma median ag year conclus risk vulvar melanoma consider lower east germani unit state sweden due rariti vulvar melanoma popul-base cancer registri hamper studi tumor detail
interleukin -12 kei factor induc cellular immun respons plai central role erad cancer present studi order creat dendrit cell -base vaccin capabl posit skew immun respons cellular immun-domin state analyz immunolog characterist vaccin efficaci dc cotransduc melanoma-associ antigen gp100 il-12 gene gp100+il12/dc us rgd fiber-mutant adenoviru vector adrgd enabl highli effici gene transduct dc gp100+il12/dc simultan express cytoplasm gp100 secretori il-12 level compar dc transduc gene alon comparison dc transduc gp100 alon gp100/dc upregul major histocompat complex class cd40 cd86 molecul cell surfac potent t-cell-stimul abil prolifer interferon-gamma secret observ characterist chang gp100+il12/dc addit administr gp100+il12/dc prepar rel low dose adrgd-il12 induc potent tumor-specif cellular immun murin b16bl6 melanoma model vaccin gp100/dc howev antitumor effect b16bl6-specif cytotox t-lymphocyt activ mice vaccin gp100+il12/dc diminish increas adrgd-il12 dose gene transduct parallel decreas present level via mhc class molecul antigen transduc anoth adrgd collect result suggest optim combin vector dose requir develop efficaci dc-base vaccin cancer immunotherapi reli genet engin simultan express tumor-associ antigen il-12
malign nasal caviti paranas sinus repres wide spectrum histolog tissu origin anatom primari site inher difficulti gener treatment approach obviou given numer variabl associ broadli-base term paranas sinu malign pnsca nevertheless major epitheli salivari malign region squamou cell carcinoma adenocarcinoma adenoid cystic carcinoma sinonas undifferenti carcinoma esthesioneuroblastoma requir surgic intervent part treatment regimen recent trend broaden indic chemotherapeut radiotherapeut option manag advanc pnsca nonepitheli malign includ wide varieti sarcoma aris region most commonli requir multimod treatment includ chemotherapi radiat surgeri definit treatment moreov proxim nasal caviti paranas sinus structur includ orbit dura brain cranial nerv carotid arteri mandat care radiolog neurolog evalu cours diseas surgic advanc permit complex tumor remov reconstruct surround structur result function cosmet improv compar earlier techniqu howev addit clinic trial necessari systemat evalu locoregion control organ-preserv strategi surviv relat varieti treatment current avail
stage cutan melanoma chang recent year increas emphasi thick ulcer prognosi earli stage diseas cutan melanoma head neck treat complet surgic resect earli stage diseas resect margin determin size depth presenc satellit lesion evalu region distant metastat diseas necessari case advanc stage diseas sentinel lymph node biopsi possibl parotidectomi neck dissect consid head neck cutan melanoma greater thick ulcer adjuv therapi indic advanc primari nodal metastat diseas mucos melanoma head neck remain difficult diseas treat high locoregion recurr rate poor prognosi despit aggress therapi
metastat melanoma carri dismal prognosi need develop treatment strategi vinca alkaloid shown consist activ melanoma patient monotherapi part combin regimen current studi evalu clinic activ toler vinorelbin first-line monotherapi patient metastat melanoma patient elig present metastat melanoma amen cur resect receiv prior system therapi advanc diseas adequ perform statu ecog 0-1 patient receiv vinorelbin dose mg/m2 dai 21-dai cycl outpati basi thirteen patient accru studi receiv cycl patient assess respons toxic surviv object respons document overal respons rate [95 confid interv 0-19 trial termin accord predetermin earli discontinu rule median progress-free surviv 3.3 month 2.3-4.3 month estim median overal surviv 8.1 month 6.0-10.2 month life-threaten toxic occur neutropenia main hematolog toxic none three episod grade 3-4 neutropenia complic infect most common non-hematolog toxic asthenia nausea neuropathi myalgia conclud vinorelbin singl agent dai 21-dai cycl favor toxic profil appear relev clinic activ patient metastat melanoma
total 935 patient extranod non-hodgkin lymphoma nhl diagnos period januari 1985 decemb 2000 kuwait cancer center serv whole popul kuwait us describ clinicopatholog epidemiolog featur extranod lymphoma kuwait extranod lymphoma account nhl observ time nhl case kuwait cancer registri analyz patholog reclassifi us latest 2000 classif most common lymphoma observ diffus larg b-cell lymphoma 58.60 follow burkitt lymphoma 3.80 pediatr group compris two third patient 77.20 most common extranod site stomach 19.70 skin 17.80 adult group larg intestin 29.80 small intestin 19.30 pediatr ag group major 73.40 adult extranod lymphoma stage ie-iie good prognosi contrari major pediatr extranod lymphoma found stage iii variat treatment polici singl agent combin chemotherapi radiotherapi combin modal treatment adopt chang time period year retrospect studi document
photodynam therapi protoporphyrin induc delta-aminolevulin acid ala mainli appli treatment human superfici skin cancer paper present studi photodynam therapi pdt implant walker tumour us subcutan administr ala improv avail ala skin determin accumul local protoporphyrin ppix subcutan administr differ concentr ala physiolog salin solut us fluoresc imag techniqu result obtain indic ppix accumul depend concentr ala tempor behavior ppix fluoresc shown clear demarc tumour zone depend post-administr time administr concentr ala solut studi need confirm encourag result defin pdt protocol us subcutan administr ala solut
goal work prospect clinic studi evalu patient suffer solid tumor us total implant venou access devic tivad determin relationship cutan contamin port insert site cathet-relat bloodstream infect crbi develop modal crbi relationship chemotherapi administr modal push/ bolu versu continu infus crbi patient method studi consecut patient need tivad posit chemotherapi administr bolu/ push continu infus everi patient perform blood cultur blood sampl port cathet cutan cultur cutan tampon skin surround implant area first eight dai postop month month insert main result studi complet patient on case port remov septic complic obtain four posit blood cultur two two same patient caus staphylococcu posit cutan tampon patient four crbi occur group patient none remain patient total number 120 tampon p&lt 0.01 two case same germ isol both skin blood none patient present local infect subcutan pocket posit cutan cultur decreas time t0-t2 24-5 t1-t3 20-5 p&lt 0.04 differ crbi incid posit cutan tampon two chemotherapi administr modal conclus cutan microbi flora primari role crbi develop tivad relationship cutan colon crbi colon reach maximum first dai catheter us system high risk colon occur both via extralumin endolumin rout differ crbi incid bolu continu infus administr
object explor vitro immun respons taxol resist associ antigen trag-3 -deriv cytotox lymphocyt ctl epitop-puls dendrit cell method hla-a2.1 restrict ctl epitop trag-3 previous identifi nonamer peptid sequenc amino acid residu trag-3 58-66 peptid synthes accord fmo procedur purifi molecular weight determin peripher blood mononuclear cell pbmc normal hla-a2.1 individu us isol dc' phenotyp identifi flow cytometri induct ctl achiev vitro stimul hla-a2.1 pbmc peptid-puls ctl activ hla-a2.1 /trag-3 melanoma cell line lb373-mel assess releas assai ifn-gamma releas elisa result synthet nonamer peptid pure determin valu molecular weight conform theoret valu phenotyp isol dc characterist matur on pbmc stimul vitro trag-3-deriv epitop-puls dc three time specif kill target cell secret high concentr ifn-gamma conclus trag-3-deriv epitop-puls elicit specif anti-tumor immun respons vitro clinic trial us tumor vaccin feasibl specif immunotherapi patient trag-3 express cancer
background increas express cathepsin contribut extracellular matrix degrad invas cancer cathepsin express under transcript control murin melanoma major promot contain potenti bind site sp1 transcript factor materi method murin melanoma cell transfect sp1 express plasmid control us matrigel invas cell motil assai presenc absenc cathepsin inhibitor ca-074me result transfect b16f1 cell sp1 express plasmid result 2.5- 5.3 -fold increas cathepsin specif activ 4.8- 5.5-fold increas invas control effect movement cell across uncoat membran ca-074me treatment result significantli reduc matrigel invas affect cell motil conclus sp1 regul capac b16f1 cell degrad reconstitut extracellular matrix part regul cathepsin express
background vascular endotheli growth factor vegf involv angiogenesi investig associ vegf serum level pre-treatment follow-up outcom patient melanoma patient method serum level vegf melanoma patient diagnosi follow-up analys enzym-link immunoassai patient follow physic examin ultrasound scan liver everi three month thorax x-rai annual vegf serum level evalu six-monthli result februari 1996 februari 2000 patient enrol nineti-two serum blood sampl collect patient median ag year rang 32-82 twenti patient male femal on patient present stage diseas stage stage iia stage iib stage iii stage two patient affect uveal melanoma melanoma predominantli locat extrem trunk 26/33 median serum level vegf diagnosi 249 ng/ml minimum ng/ml maximum 1215 ng/ml median surviv patient 45.1 month median time-to-progress 36.7 month patient lower higher serum vegf valu show statist signific differ surviv contrast high serum vegf valu associ shorter diseas-free surviv compar lower valu median df month 0.048 log-rank test conclus result suggest serum vegf prognost valu melanoma
pilot studi conduct assess toler effect host immun post-surgeri adjuv treatment melanoma patient anti-angiogen agent tamoxifen tam mg/die p.o daili combin immunomodul cytokin i.e recombin interleukin-2 il-2 mui/m2 s.c dai alpha-2b-interferon ifn mui/m2 i.m dai start cycl dai total cycl fifti patient pt enter studi male femal median ag year rang 25-75 perform statu ecog melanoma stage iia patient stage iib patient stage iii patient preliminari vitro studi show tam doe interfer up-regul natur immun induc ifn il-2 ifn il-2 normal peripher blood mononuclear cell mnc clinic studi indic protocol well toler increas lak activ patient mnc observ dai mean diseas-free interv month pt aliv year follow-up investig perform test effect protocol random studi
respons dna damag p53 accumul regul express sever gene includ cyclin-depend kinas inhibitor p21 cell undergo p21 depend cell cycl arrest allow dna damag repair apoptosi bax death promot member bcl-2 famili plai central role regul commit program cell death breslow thick most import factor predict prognosi cutan malign melanoma order defin role cyclin depend kinas inhibitor apoptosi regul invas malign melanoma investig express p21 bax protein observ signific high p21 express associ increas breslow thick spearman correl analysi 0.01 addition clark level tumour express significantli lower p21 posit clark level iii 0.006 similarli thick tumor show higher bax express 0.012 result suggest role p21 express complic melanocyt skin cancer abnorm regul abnorm function cell cycl regul occur develop progress malign melanoma order understand role bax express thick malign melanoma invas biologi compar analyt studi apoptosi regul need
ollier's diseas rare diseas character constitut bone dysplasia multipl enchondroma combin haemangioma chondromatos known maffucci's syndrom malign degener bone dysplasia chondrosarcoma well-known complic lesion base skull except slowli grow low-grade malign tumour three case chondrosarcoma base skull occur on patient marfucci's syndrom two patient ollier's diseas report case discuss light literatur multidisciplinari approach compris surgeri radiotherapi achiev good result
organ network patient recruit main concern facil us charg particl experi choroid melanoma nice demonstr possibl creat novo protontherapi center treat suffici number patient influenc open facil analyz
tumor healthi tissu sampl irradi mev proton sampl expos dose subsequ examin raman spectroscopi analysi intens characterist peak function radiat dose exhibit differ trend two type tissu
object develop techniqu treat whole-bodi skin us linear acceler electron beam energi 6-mev short treatment distanc materi method mev high dose rate total skin electron irradi mode linear acceler us beam profil percentag depth dose patient plane measur differ beam angul result treatment distanc ssd 292 us acryl scatter-degrad 4mm thick beam penetr calcul dose li 1.6 singl beam clinic beam uniform vertic profil obtain us beam treatment posit gantri angl 700 900 1100 conclus implement modifi stanford techniqu total skin electron beam irradi short treatment distanc us acryl scatter-degrad three beam angul produc uniform beam treatment plane
